NCT06905314Not yet recruitingPhase 1
A Single Ascending Dose of HRS-4029 in Healthy Subjects
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HRS-4029 Following a Single Dose in Healthy Subjects
Source: ClinicalTrials.gov · Last updated 1 Apr 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The study is being conducted to evaluate the safety, tolerability and pharmacokinetics of HRS-4029 following a single intravenous dose administration in healthy subjects.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 55 (estimated)
- First submitted
- 25 Mar 2025
- Start date
- Apr 2025
- Primary completion date
- Oct 2025
- Lead sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd
- Diseases
- Stroke
- NCT number
- NCT06905314
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 55
- From Apr 2025 to the primary completion date, Oct 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Smoke ≥5 cigarettes per day within 3 months prior to the study
Other illness
- Diseases with abnormal clinical manifestations that occurred before screening or are currently occurring and need to be excluded.
- Subjects with positive tests for infectious diseases.
- Unable to tolerate venipunctures or have a history of fainting needles and blood.
- History of drug abuse.
Lab values
- Vital signs, physical examination, 12-lead electrocardiogram,or laboratory examination deemed clinically significant by the investigator .
Other
- Female who are pregnant or breastfeeding.
- Historic abuse of alcoholic beverages
- Other reasons that the investigator consider it inappropriate to participate in the trial.
Who the study is looking for
- Age between 18 to 55 years.
- Body mass index (BMI) of 19.0 to 28.0 kg/m2 (inclusive).
- Agreed to take effective contraceptive measures during and 3 months after the last dose of the study period.
- Understand in detail the content, procedure and possible adverse effects of the trial, and voluntarily sign the written informed consent form (ICF).
Age in the registry: 18 years to 55 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| China-Japan Friendship Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.